GlobeNewswire: Nabriva Therapeutics US, Inc Contains the last 10 of 214 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:16:15ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/01/06/2584338/0/en/Nabriva-Therapeutics-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics Provides Corporate Update2023-01-06T12:01:00Z<![CDATA[-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations-]]>https://www.globenewswire.com/news-release/2022/11/28/2563012/0/en/Nabriva-Therapeutics-Announces-Positive-Topline-Results-from-Phase-1-Trial-of-XENLETA-lefamulin-in-Adult-Patients-with-Cystic-Fibrosis.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis2022-11-28T12:01:00Z<![CDATA[- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects –]]>https://www.globenewswire.com/news-release/2022/11/10/2553732/0/en/Nabriva-Therapeutics-Pivoting-Strategic-Focus-Reports-Third-Quarter-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update2022-11-10T21:01:00Z<![CDATA[- Shifted Focus to SIVEXTRO to Enable Cost Cutting -]]>https://www.globenewswire.com/news-release/2022/11/07/2549506/0/en/Nabriva-Therapeutics-to-Report-Third-Quarter-2022-Financial-Results-and-Recent-Corporate-Highlights-on-November-10-2022.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 20222022-11-07T12:01:00Z<![CDATA[DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its third quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, November 10, 2022. Nabriva’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.]]>https://www.globenewswire.com/news-release/2022/09/15/2516745/0/en/Nabriva-Therapeutics-Announces-Date-of-1-for-25-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split2022-09-15T11:01:00Z<![CDATA[DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-25 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 16, 2022.]]>https://www.globenewswire.com/news-release/2022/09/06/2510222/0/en/Nabriva-Therapeutics-to-Participate-in-the-H-C-Wainwright-24th-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference2022-09-06T11:01:00Z<![CDATA[DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 24th Annual Global Investment Conference. Management will also host investor meetings September 12-14, 2022.]]>https://www.globenewswire.com/news-release/2022/08/11/2496605/0/en/Nabriva-Therapeutics-Completes-Patient-Enrollment-in-Phase-1-Trial-of-XENLETA-lefamulin-in-Adult-Patients-with-Cystic-Fibrosis.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis2022-08-11T11:01:00Z<![CDATA[- Topline Data Expected First Quarter 2023 - - Topline Data Expected First Quarter 2023 -]]>https://www.globenewswire.com/news-release/2022/08/03/2491741/0/en/Nabriva-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Provides-a-Corporate-Update.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update2022-08-03T20:01:00Z<![CDATA[-Net Product Sales of $8.7M Grew 25% versus Q2 2021-]]>https://www.globenewswire.com/news-release/2022/07/20/2483154/0/en/Nabriva-Therapeutics-to-Report-Second-Quarter-2022-Financial-Results-and-Recent-Corporate-Highlights-on-August-3-2022.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 20222022-07-20T20:05:00Z<![CDATA[DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Wednesday, August 3, 2022. Nabriva’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.]]>https://www.globenewswire.com/news-release/2022/07/18/2480937/0/en/Nabriva-Therapeutics-Expands-XENLETA-lefamulin-Presence-with-Exclusive-Agreement-with-Er-Kim-Pharmaceuticals.html?f=22&fvtc=4&fvtv=27611Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals2022-07-18T11:01:00Z<![CDATA[DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into an exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the oral and intravenous formulations of XENLETA® (lefamulin).]]>